ImmunoGen Management
Management criteria checks 3/4
ImmunoGen's CEO is Mark Enyedy, appointed in May 2016, has a tenure of 7.75 years. total yearly compensation is $5.42M, comprised of 14% salary and 86% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $18.25M. The average tenure of the management team and the board of directors is 1.3 years and 12.1 years respectively.
Key information
Mark Enyedy
Chief executive officer
US$5.4m
Total compensation
| CEO salary percentage | 14.0% |
| CEO tenure | 7.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.3yrs |
| Board average tenure | 12.1yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$74m |
| Jun 30 2023 | n/a | n/a | -US$180m |
| Mar 31 2023 | n/a | n/a | -US$240m |
| Dec 31 2022 | US$5m | US$759k | -US$223m |
| Sep 30 2022 | n/a | n/a | -US$201m |
| Jun 30 2022 | n/a | n/a | -US$161m |
| Mar 31 2022 | n/a | n/a | -US$129m |
| Dec 31 2021 | US$7m | US$735k | -US$139m |
| Sep 30 2021 | n/a | n/a | -US$71m |
| Jun 30 2021 | n/a | n/a | -US$56m |
| Mar 31 2021 | n/a | n/a | -US$49m |
| Dec 31 2020 | US$5m | US$714k | -US$44m |
| Sep 30 2020 | n/a | n/a | -US$71m |
| Jun 30 2020 | n/a | n/a | -US$70m |
| Mar 31 2020 | n/a | n/a | -US$89m |
| Dec 31 2019 | US$4m | US$710k | -US$104m |
| Sep 30 2019 | n/a | n/a | -US$151m |
| Jun 30 2019 | n/a | n/a | -US$176m |
| Mar 31 2019 | n/a | n/a | -US$174m |
| Dec 31 2018 | US$9m | US$687k | -US$169m |
| Sep 30 2018 | n/a | n/a | -US$140m |
| Jun 30 2018 | n/a | n/a | -US$150m |
| Mar 31 2018 | n/a | n/a | -US$117m |
| Dec 31 2017 | US$3m | US$670k | -US$96m |
Compensation vs Market: Mark's total compensation ($USD5.42M) is about average for companies of similar size in the US market ($USD7.66M).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
CEO
Mark Enyedy (59 yo)
7.8yrs
Tenure
US$5,422,421
Compensation
Mr. Mark Joseph Enyedy serves as Independent Director of BioMarin Pharmaceutical Inc. since December 27, 2023. He is Non-Executive Director at Ergomed plc since June 10, 2021. He has been the Chief Executi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.8yrs | US$5.42m | 0.22% $ 18.3m | |
| Senior VP & Chief Business Officer | 3.7yrs | US$1.84m | 0.027% $ 2.3m | |
| Chief Medical Officer | 1.2yrs | US$3.81m | 0.00050% $ 41.8k | |
| Senior VP & Chief Financial Officer | less than a year | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Senior VP | 1.3yrs | no data | 0.00037% $ 30.9k | |
| Senior Director of Corporate Communications & Investor Relations | no data | no data | no data | |
| Senior VP & Chief HR Officer | 5.6yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs & Quality | no data | US$1.27m | 0.0079% $ 657.0k | |
| Senior VP & Chief Commercial Officer | less than a year | no data | no data |
1.3yrs
Average Tenure
59.5yo
Average Age
Experienced Management: IMGN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.8yrs | US$5.42m | 0.22% $ 18.3m | |
| Independent Chairman | 16.8yrs | US$257.80k | 0% $ 0 | |
| Independent Director | 12.1yrs | US$217.80k | 0.038% $ 3.2m | |
| Independent Director | 12.1yrs | US$227.80k | 0% $ 0 | |
| Independent Director | 2.4yrs | US$175.00k | 0.0011% $ 96.1k | |
| Independent Director | 16.3yrs | US$220.30k | 0.0037% $ 312.6k | |
| Independent Director | 6.1yrs | US$210.30k | 0.0020% $ 168.0k | |
| Independent Director | 12.3yrs | US$225.30k | 0.023% $ 1.9m | |
| Independent Director | 2.3yrs | US$146.65k | 0% $ 0 |
12.1yrs
Average Tenure
64yo
Average Age
Experienced Board: IMGN's board of directors are seasoned and experienced ( 12.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/12 04:54 |
| End of Day Share Price | 2024/02/12 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ImmunoGen, Inc. is covered by 19 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Wang | Brean Capital |
| John Newman | Canaccord Genuity |
| Mara Goldstein | Cantor Fitzgerald & Co. |